ACTIVITY DESCRIPTION
This interactive, on-demand activity introduces Mr J, a man with diabetes, sleep apnea, and a BMI greater than 30 kg/m2, who is concerned about his long-term health and wants to lose weight. In 30 minutes, you can review this case-based activity and learn about:
- Treating obesity versus obesity-related comorbidities
- The amount of weight loss needed to improve diabetes and other comorbidities
- Weight-loss approaches, such as diet and lifestyle changes, counseling sessions, and pharmacotherapy
- Working with patients to optimize their weight-loss plans
LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
- Describe the effects of weight loss on obesity-related comorbidities
- Evaluate the efficacy and safety data for available pharmacologic therapies for obesity management
- Implement weight-loss management goals to address obesity-related comorbidities
- Recognize when weight-loss pharmacologic therapy is needed to help patients with obesity-related comorbidities lose and maintain their weight
FACULTY
W. Timothy Garvey, MD
Butterworth Professor and Chair
Department of Nutrition Sciences
University of Alabama at Birmingham
Director, UAB Diabetes Research Center
GRECC Investigator and Staff Physician
Birmingham VA Medical Center Birmingham, AL
FACULTY BIOGRAPHY
W. Timothy Garvey, MD, is Butterworth Professor of Medicine and Chair, Department of Nutrition Sciences, at the University of Alabama at Birmingham. He earned his medical degree, cum laude, from St. Louis University, St. Louis, Missouri. He completed residency training in Internal Medicine at Barnes-Jewish Hospital, Washington University, St. Louis, MO, followed by a clinical fellowship in endocrinology and metabolism at the University of Colorado Health Sciences Center, Denver, and the University of California, San Diego School of Medicine.
Dr Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, type 2 diabetes, and obesity. He has directed an independent laboratory since 1987 supported by the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases/National Heart, Lung, and Blood Institute), the Department of Veterans Affairs, the American Heart Association, the Juvenile Diabetes Foundation International, the American Diabetes Association, and other agencies. He has served as the Principal Investigator of the NIH-funded Diabetes Research Center since its initiation in 2008. He has provided service as a member of national research review committees for the Juvenile Diabetes Research Foundation, the American Diabetes Association, the VA Merit Review Program, and the National Institutes of Health. Dr Garvey currently serves on the editorial boards of the peer-reviewed publications Diabetes Care, Metabolic Syndrome & Related Disorders, Cardiorenal Medicine, and Journal of Clinical Endocrinology and Metabolism. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the Endocrine Society, the American Diabetes Association, the Obesity Society, and the American Association of Clinical Endocrinologists.
DISCLOSURE STATEMENTS
In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.
The following faculty and staff members have disclosures to be made:
W. Timothy Garvey, MD
Speaker’s Bureau: Merck
Consultant/Advisory Board: Boehringer Ingelheim; Eisai Inc; Janssen Pharmaceuticals, Inc; LipoScience, Inc; Novo Nordisk; Takeda Pharmaceuticals International, Inc; Vivus, Inc
Investigator (contracted research, grants, etc): AstraZeneca; Eisai Inc; Merck; Sanofi US; Vivus, Inc; Weight Watchers International, Inc
Ownership Interests: Bristol-Myers Squibb; Eli Lilly and Company; Merck; Novartis; Pfizer Inc.
Dr Garvey does not discuss information related to any non–FDA-approved or investigational use of any product/device.
Spire Learning
Jeanne Prater
Shareholder (spouse): Johnson & Johnson
Employee (spouse): Novo Nordisk
The following have no financial relationships with commercial interests to disclose:
Independent Content Reviewer
Bernard Abrams, MD
Clinical Professor of Neurology
University of Missouri School of Medicine at Kansas City
Kansas City, MO
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence based, and commercially balanced.
Bernard Abrams, MD, content reviewer, and Jennifer Hodge, Dannemiller project manager, have no financial relationships with commercial interests.
Spire Learning
Lauren Waters, Program Director; Erin Franceschini, MS; Jaime Symowicz, PhD; and Kashemi Rorie, PhD, have no financial relationships with commercial interests.
DISCLAIMER
The content and views presented in this educational activity are those of the presenter and do not necessarily reflect those of Dannemiller, Spire Learning, Takeda Pharmaceuticals International, Inc., U.S. Region, or Orexigen. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
DISCLOSURE OF OFF-LABEL USE
This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in this educational activity are those of the faculty. Please refer to official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity.
LEVELS OF EVIDENCE
Strength of recommendations ratings from the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults have been provided for patient care recommendations described in this activity and are based on the grading scale below.
| NHLBI Grading of the Strength of Recommendations |
| Grade | Strength of Recommendation |
| A | Strong recommendation
There is high certainty based on evidence that the net benefit is substantial. |
| B | Moderate recommendation
There is moderate certainty based on evidence that the net benefit is moderate to substantial, or there is high certainty that the net benefit is moderate. |
| C | Weak recommendation
There is at least moderate certainty based on evidence that there is a small net benefit. |
| D | Recommendation against
There is at least moderate certainty based on evidence that there is no net benefit or that risks/harms outweigh benefits. |
| E | Expert opinion
(“There is insufficient evidence or evidence is unclear or conflicting, but this is what the Work Group recommends.”) |
| N | No recommendation for or against
(“There is insufficient evidence or evidence is unclear or conflicting.”) |
TARGET AUDIENCE
This activity is designed for physicians, physician assistants (PAs), and nurse practitioners (NPs) with an interest in the management of obesity, particularly those practicing in primary care and endocrinology.
ACCREDITATION
Physicians, Physician Assistants (PAs),
Nurse Practitioners (NPs)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and Spire Learning. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
Dannemiller designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for the educational activities certified for AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME.
Dannemiller is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 090419. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards. It provides 0.50 credits of continuing education (which includes 0.25 hours of pharmacology).
METHOD OF PARTICIPATION
This activity has no fee and should take approximately 30 minutes to complete. Participants should first read the objectives and other introductory CME information, then complete the pre-assessment and participate in the online case activity. To receive credit for this activity, participants must complete the post-assessment with a passing score of 70% and then complete the evaluation. This credit is valid through September 15, 2016. No credit will be given after this date. In the event you have questions about this activity or are unable to print the certificate, please e-mail Lauren Waters at lwaters@spirelearning.com, and a certificate will be e-mailed within 2 weeks.
This educational activity is jointly provided by Dannemiller and Spire Learning.
This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region, and Orexigen.